Slovenian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
staurosporine/slabost navzea
Povezava se shrani v odložišče
5 rezultatov
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
BACKGROUND
PKC412 (N-benzoyl-staurosporine), an oral inhibitor of protein kinase C, is capable of cell cycle inhibition and is endowed with anti-angiogenic properties. This dose-finding phase I study was designed to establish the maximum tolerated dose (MTD) of PKC412 when combined with
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
OBJECTIVE
4'- N -Benzoyl-staurosporine (PKC412) is an orally available staurosporine derivative that inhibits protein kinase C. The objectives of this phase I trial were to determine the maximum tolerated dose (MTD), the dose limiting toxicities (DLTs), and the pharmacokinetics of PKC412 when
Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Aberrations in cell cycle control occurs in the majority of human malignancies due to inactivation of tumor suppressor gene Rb by the phosphorylation induced by "hyperactive" cyclin-dependent kinases. Thus, it is quite reasonable to design cdk modulators for the prevention and treatment of human
The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Midostaurin (PKC412A), N-benzoyl-staurosporine, potently inhibits protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR and FLT3 tyrosine kinases. In mice, midostaurin slows growth and delays lung metastasis of melanoma cell lines. We aimed to test midostaurin's safety, efficacy and biologic
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
OBJECTIVE
N-Benzoyl staurosporine (PKC412) is a protein kinase C inhibitor with antitumor activity in laboratory models. We determined the toxicity of oral PKC412 administered daily for repeat cycles of 28 days.
METHODS
Thirty-two patients with advanced solid cancers were treated at seven dose
Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo
- Deluje v 55 jezikih
- Zeliščna zdravila, podprta z znanostjo
- Prepoznavanje zelišč po sliki
- Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
- Preberite znanstvene publikacije, povezane z vašim iskanjem
- Iščite zdravilna zelišča po njihovih učinkih
- Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti
Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah
